Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gastrointestinal Cancers
•
Rectal Cancer
•
Medical Oncology
•
Colorectal Cancer
•
NCI-CCC Tumor Board Question
•
NCI-CCC GI Tumor Board Question
•
Memorial Sloan Kettering
Would you offer adjuvant 5-FU-based therapy for a patient with adenocarcinoma involving the ischiorectal fossa thought to be tailgut cyst adenocarcinoma who achieved a pCR to 5-FU + RT followed by surgery?
(IHC stained like colorectal).
Related Questions
For patients with rectal cancer being treated along PROSPECT paradigm, would you extrapolate from the IDEA literature and offer 3 months of CAPOX neoadjuvantly, without adjuvant therapy?
What do you recommend for patients with stage 3 MSI-H colorectal cancer who are ineligible for oxaliplatin-based adjuvant therapy?
Would you recommend adjuvant capecitabine and radiation in addition to adjuvant FOLFOX for a patient with resected pT3N2 rectosigmoid adenocarcinoma with other high-risk pathologic features?
What are your top takeaways in GI Cancers from ASCO 2023?
Would you recommend additional post-operative chemoradiation for a T2N1 proximal rectal cancer having received adjuvant capecitabine/oxaliplatin?
How would you manage a positive margin after APR for a patient who received neoadjuvant CAPOX alone due to previous remote prostate cancer radiation?
Would you offer chemotherapy to an elderly patient with MSI-H stage 3 colon cancer who cannot tolerate oxaliplatin?
Would you offer adjuvant chemotherapy or radiation to a resected MSS T3N0 high-rectal lesion with low anterior resection without pre-op therapy?
How would you approach a patient with clinical T3N1 anorectal malignant melanoma referred by a surgeon for neoadjuvant therapy?
How will the PROSPECT trial presented at ASCO 2023 change your current management of early rectal cancer?